Langer lab makes synthetic 'good cholesterol' for cardiovascular drug delivery

MIT professor and biotech entrepreneur Robert Langer and colleagues have created a synthetic version of the natural high-density lipoprotein (HDL)--or "good cholesterol"--for use in drug delivery to treat cardiovascular diseases such as atherosclerosis. The team used microfluidics to construct the µHDLs, which are easy-to-manufacture versions of the natural nanoparticle, according to the American Chemical Society. The study appeared in the journal ACS Nano. The work drew funding from NIH, the National Cancer Institute, the Prostate Cancer Foundation, the American Heart Association and the National Heart, Lung, and Blood Institute. More | Abstract

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…